Фармакоэкономика
теория и практика

VIII конгресс с международным участием
«Развитие фармакоэкономики и фармакоэпидемиологии в Российской Федерации»

Методологические основы моделирования при проведении фармакоэкономических исследований:
разные уровни сложности и разная ценность полученных результатов
VIITH CONGRESS WITH INTERNATIONAL PARTICIPATION «DEVELOPMENT OF PHARMACOECONOMICS AND PHARMACOEPIDEMIOLOGY IN THE RUSSIAN FEDERATION»

Akimova Yu.I.

Laboratory of pharmacoconomics of Research institute of pharmacy  I.M. Sechenov First Moscow State Medical University

Summary: Modern health care and pharmaceutical industry can not be imagined without pharmacoeconomic studies, the results of which can justify the inclusion of medicines in the programs of medical care and prevention on different levels, as well as the conscious approach to the choice of health technologies in terms of the rational decision-making.

Keywords: Congress with international participation «Development of pharmacoconomics and pharmacoepidemiology in the Russian Federation», pharmacoconomics, pharmacoepidemiology, Rostov-on-Don.

Experts from various regions of the Russian Federation and other countries, including heads of health management, Chief physicians of medical institutions, representatives of academic sphere, employees of the pharmaceutical industry and other specialists from the related fields took part in the VIITH Congress titled «Development of pharmacoconomics and pharmacoepidemiology in the Russian Federation», held on March 4-5, Rostov-on-Don.

In the scopes of the two-day program, including plenary and more than 10 specialized sessions, the participants could get acquainted with the results of the recent pharmacoeconomic studies, as well as obtain actual data on various aspects of medicine supply in Russia and other countries. One of them, the need for and availability of innovation in the health care system, had been extensively covered in the plenary. The international experience on this issue was presented by Ms. Nina Sautenkova, Program Manager of Pharmaceutical Policy in CIS of the WHO European Bureau. The rapporteur noted the acuteness of the problem for Europe, in particular, related to the lack of a common method for assessments and methods over the market entry, as well as related to rarely impartial decision-making in regards to the innovative technologies.

Among the primary factors needed for the incorporation of innovative technologies, Ms. Sautenkova primarily mentioned the availability of guarantees on genuine innovations, the possibilities of realization of technologies in the health system and availability of sufficient financial resources.

The presentation of Ms. Rosa Yagudina, professor, chief of the Department of Organization of Medicine Supply and Pharmacoeconomics, the First MSMU after Sechenov I.M., was dedicated to the peculiarities of pharmacoeconomic evaluation of innovations in medicine supply. Obviously, in most cases, the incorporation of innovative medicaments and medical technologies that can improve the quality and duration of patients’ life requires a lot of additional costs. The issue for their justification underlines the necessity for adoption of new tools, such as multi-criteria decision analysis (Multi Criteria Decision Analysis - MCDA). (Fig. 1).

**Diagram:**

- **MCDA...**
- **Identification of stakeholders**
- **Problem considered**
- **Selection of criterion of analysis**
- **Defining the attributes of criterion**
- **And assessments of the highlighted criterion**
- **Stakeholders**
- **To determine the scales criterion**
- **Instrumental and methodological support**
- **Decomposition of problem and correct placement of priorities to make clear decisions**

The decision-making structure through the MCDA.

Akimova Yu.I. mob +7 962 989 57 37, e-mail:  yu.akimova@inbox.ru

PHARMACOECONOMICS: theory and practice Volume 2, number 2, 2014
These and other methods are applied in the framework of the health technology assessment (HTA). This is an effective tool for management decisions, based on evidence-based medicine, cost optimization and efficient use of public funds. The HTA necessity is dictated by time, and its worldwide popularity is growing every year. At the congress, Elena Telnova, representing the National Institute of Public Health of Federal agency of scientific organizations, presented her report titled “Has the HTA time come for the Russian Federation?” The expert identified the peculiarities of the HTA incorporation in Russia, due to the regional differences in administrative structures, budget and personnel capabilities of subjects requiring an individual approach for each region.

Despite a number of obstacles in regards to the implementation of HTA - the lack of indicators of effectiveness in the implementation of state programs, the transition from the payment for the process to the payment for the outcomes and others, Elena Telnova noted the positive dynamics in the incorporation of HTA (Fig. 2).

Positive tendencies in HTA

Increase in the number of conferences, symposiums and congresses with the agenda on HTA (including regional level)

Participation in international congresses and organizing international events featuring the theme of HTA in Russia

A permanent increase of pharmacoeconomic studies and publications is recorded

70-80% studies on VEN medicaments

The peculiarities of the evaluation system in Turkey were presented by Seda Yilmaz, Manager of pharacoeconomics, pricing and preferential supply at the Bayer company. The HTA relevance for this country is not in doubt. Health care reforms have initiated the development of the reference pricing and reimbursement on the basis of clinical efficacy and results of analyzes of the «cost-effectiveness» and «impact on the budget.» However, the implementation of HTA in Turkey still constrains lack of qualified personnel, infrastructure and clear evaluation criteria, as mentioned by the expert.

During the first and second days of the Congress special sessions were organized on issues of relevance to various specialists: experts in pharmacoeconomics, health managers, practitioners.

Several studies were presented on such a high-cost nosology as the rare diseases, breast cancer, cancer in nephrology, diabetes, diseases that might lead to blindness. For the first time in the scopes of the Congress were discussed the pharmacoeconomic approaches in the preventive vaccines. The actuality of it is very high at the moment due to the frequent changes in the national calendar of preventive vaccinations and the necessity of incorporation of new medicines, as well as in regards to the optimization of the existing vaccination regimens.

The problems and solutions for organizing the medicine supply on the regional level were discussed by the participants of the roundtable. The regional representatives noted both the common problems and characteristics of specific subjects in regards to the issues of providing medications to specific groups, and in relation to the order of the formation of the list of medicines and funding from local budgets.

As a conclusion of the Congress, the results of the previously announced contest for the scientific works among the young scholars were summarized and presented to the attendees. This year the organizers offered the contest participants to introduce the results of their studies not only in the traditional format of poster presentations but also to switch on the recorded video presentations.

The first place was shared between A.Tikhonov, a representative of the Military Medical Academy named after Kirov S.M. (Saint Petersburg) for the study on «Development of system of regulation of medicines for the troop level of medical service of the Russian armed forces in times of peace» (supervisor – Yu.Miroshnichenko) and V.Babi, fifth-year student of the First Moscow State Medical University after Sechenov I.M. for the publication titled «Pharmacoeconomic study on pharmaceutical care for children with diseases of the joints» (Supervisor – I. Spichak).

The committee organizers and members congratulated the winners of the contest and wished them continued success.

The Congress was organized with the support of the leading pharmaceutical companies:

- Alcon Pharmaceuticals® LLC
- Amgen® LLC
- Astrazeneca Pharmaceuticals® LLC
- Bayer® JSC
- BAXTER® CJSC
- Bristol-Myers Squibb® LLC
- GENERIUM® JSC
- GlaxoSmithKline Trading® JSC
- Johnson & Johnson® LLC
- IPSEN® LLC
- Merck® Ltd
- Promomed® Company
- Novartis Pharma® LLC
- Novo Nordisk® Ltd
- Roche-Moscow® Ltd
- Sanofi-Aventis Group® JSC
- Celgene® International Holdings Corporation
- Fresenius Kabi® LLC
- Eisai® Ltd
- Promomed® Company
- Novartis Pharma® LLC
- Novo Nordisk® Ltd
- Roche-Moscow® Ltd
- Sanofi-Aventis Group® JSC
- Celgene® International Holdings Corporation
- Fresenius Kabi® LLC
- Eisai® Ltd